May 1, 2020 / 3:44 PM / a month ago

BRIEF-Abbvie Says Saw Modest Impact To New Patient Starts For Some Drugs Due To COVID-19 Restrictions: Q1 Conf Call

May 1 (Reuters) - Abbvie Inc:

* ABBVIE INC SAYS SAW MODEST IMPACT TO NEW PATIENT STARTS FOR SOME DRUGS DUE TO COVID-19 RESTRICTIONS IN Q1: CONF. CALL

* ABBVIE INC CEO SAYS EXPECTS PRONOUNCED IMPACT ON ALLERGAN’S AESTHETICS BUSINESS DUE TO COVID-19: COF. CALL

* ABBVIE INC CEO SAYS EXPECTS ALLERGAN’S BOTOX AESTHETICS BUSINESS TO REBOUND QUICKLY AFTER INITIAL IMPACT DUE TO COVID-19: CONF. CALL

* ABBVIE INC EXPECTS U.S. HUMIRA SALES GROWTH OF ABOUT 7% IN 2020: CONF. CALL

* ABBVIE CEO SAYS U.S. HUMIRA SALES FORECAST FOR 2020 ASSUMES MORE PATIENTS WILL SHIFT TO MEDICAID PLANS Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below